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              Introduction  
                         Drug induced liver injury (DILI) is a problem of increasing significance. It is a 
long standing concern in the treatment of tuberculosis (TB). Pathogenesis and types of anti-
TB DILI ranges from hepatic adaptation to hepatocellular injury. Hepatotoxicity is the most 
serious side effect of anti tuberculosis treatment (ATT) and it causes substantial morbidity as 
well as mortality and can diminish the efficacy of treatment. Anti-TB DILI can present as 
asymptomatic transaminase elevation to serious hepatotoxicity in the form of hepatic failure-
Acute, Sub acute or acute on chronic liver failure. Systematic steps for prevention and 
management of TB DILI are recommended. 
 
  The incidence of ATT induced hepatotoxicity varies from 8-30% in different studies 
[43, 44]. More serious liver disease induced by ATT occurs in 0.01% to0.03% of patients. 
Several risk factors for anti-TB DILI have been described, including age, sex, race, pre-
existing liver disease, extent of tuberculosis, alcohol consumption, low body mass index, 
acetylator status, use of hepatotoxic drugs, and a high dosage of ATT in relation to body 
weight.    
 
  Isoniazid – induced hepatotoxicity usually occurs soon after the start of ATT, but can 
still occur at any later time point during treatment. Continuation of isoniazid despite 
symptoms has been associated with a severe clinical course and fatal outcome. Pyrazinamide 
hepatotoxicity usually occurs after longer periods of treatment but again this is not a rule. 
Isoniazid can result in acute liver failure (ALF) but pyrazinamide more often leads to sub 
acute hepatic failure (SAHF). In patients in whom liver function recovers after 
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discontinuation of ATT, the drugs can often be restarted by sequential introduction along with 
frequent monitoring of liver function tests (LFT).   
 
  International guidelines issued by the American Thoracic Society, the British 
Thoracic Society and European Respiratory Society Task Force all state that baseline 
determination of liver function should be carried out before ATT is started in patients with 
TB. Regular monitoring of LFT is advocated in patients with underlying liver disease or 
known risk factors for liver disease.     
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                    Aims                          
1) To study the clinical profile and to assess the prognostic factors and outcome of anti-TB 
Drug induced liver injury 
2) To assess risk factors for ATT induced liver failure (compared to ATT induced hepatitis). 
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          Review of literature 
 
                             The liver plays a major role in metabolism of drugs and hence is 
susceptible to its toxic and deleterious effects. It is an important cause of liver failure in the 
West and East. It is an important cause for asymptomatic transaminitis as well as acute liver 
failure. The mortality in acute liver disease due to drugs is approximately 10% [2]. Since 
there is no specific test for confirmation, the diagnosis mainly rests on the suspicion and 
causality assessment and then on discontinuation of the suspected drug following which liver 
function tests gradually improves. DILI is also a serious concern for the pharmaceutical 
companies. The safety and toxicology issues are the major concerns in clinical trials. 
 
Definitions  and  Importance 
 
                                 Drugs are a relatively common cause of liver injury. Drug induced liver 
injury(DILI) is defined as abnormalities of liver biochemical test levels, particularly an 
increase in the serum alanine aminotransferase (ALT), alkaline phosphatase, or bilirubin 
level, to more than twice the upper limit of normal.[1] .Over 300 drugs have been implicated 
in drug induced liver injury , but only 50 are reliably described. Some drugs cause predictable 
dose dependent liver injury (acetaminophen and methotrexate) where as in most cases it is 
unpredictable. These unpredictable DILI are mostly either idiosyncratic or immune mediated. 
In most cases of DILI, liver biopsy tells us about the extent of injury rather than the cause. 
Hence the diagnosis is often based on i) temporal relationship between the drug ingestion and 
liver injury ii)exclusion of other causes, iii)the presence of extra hepatic manifestations  of 
drug hypersensitivity(immune allergic reaction),iv) findings on liver biopsy.[2] 
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Epidemiology of  Drug-Induced Liver Injury. 
                                DILI is an important cause of withdrawal of drug from the market.[3,4,5]. 
The epidemiology of DILI is poorly understood because of the limited active and passive 
reporting and surveillance systems in place and the lack of standardized criteria for its 
diagnosis. There are many retrospective and prospective studies describing the incidence and 
risk factors associated with DILI in the literature.. The risk of DILI in a population ranges 
from 1 in 10,000 to 1 in 100,000 people exposed [6].DILI accounts for 5%-10% of patients 
admitted because of acute hepatitis [7-10] . A French study has shown the incidence of DILI 
to be 14per100, 000 patients.[3] This is definitely an under estimation as many cases as 
subclinical. Many herbal and dietary supplements are also reported to cause DILI especially 
in South East Asia [11].  
 
                                     Drugs are the most common causes of fulminant hepatic failure in the 
West[12-14].In the West, acetaminophen has been reported to be the single most common 
cause of acute liver failure where as in South Asia anti tuberculous (anti-TB) treatment is the 
most common cause of drug induced liver failure[15].Idiosyncratic drug reactions are 
presumed to account for 13% of liver failure in US and 17% in Sweden.[3,12,13].Early 
recognition of DILI is important so that continued exposure can be avoided thus preventing 
severe liver dysfunction. Studies have shown that prognosis for patients with drug induced 
liver failure is poor with mortality ranging from 60%-80% without liver transplantation.[12-
14]. The US ALF study group has shown that idiosyncratic drug injury (13%) was second 
only to acetaminophen overdose (39%) following the analysis of their registry during 1998-
2001[16]. In a recent study published from Northern India, Ramesh Kumar et al has reported 
that the mortality in patients of Anti Tuberculous treatment( ATT) induced acute liver failure 
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(ALF) is 67%[15].In an another study from Southern India , Devarbhavi H et al showed an 
overall mortality of 21% in   anti-TB DILI.[17]. Agal  S et al noted  mortality of 16.6% in 
ATT induced hepatitis in their study from Western India [18].Drug induced ALF accounts for 
approximately 20% of ALF in children, most common aetiology being acetaminophen (15%), 
followed by anti tuberculous drugs  and anti epileptic therapy. 
 
                             Over the last decade, the three prospective registries that significantly 
enhanced our knowledge of DILI are the Regional Registry of Hepatotoxicity in southern 
Spain, the U.S. Acute Liver Failure Study Group (ALFSG), and the Drug-Induced Liver 
Injury Network (DILIN). The importance of these registreries is that they provide an 
opportunity to study the mechanisms, aetiology, associated risk, case fatality in DILI and 
helps to find out preventive measures for these serious and potentially fatal drug reactions. 
There is a lack of of reporting of DILI from developing countries including the Indian 
subcontinent. An ageing population, increasing co-morbidities, and diseases such as 
tuberculosis, HIV, epilepsy which are more prevalent in developing countries, (which are all 
treated with multiple drugs,) results in an overall increase in DILI in developing countries. 
 
                         There is a paucity of data regarding DILI from the India although we have 
many case reports of ATT induced hepatitis. In a recent study,( in a retrospective analysis of 
consecutive collected data of patients with DILI, seen over a 12-year period) Devarbhavi .H 
et al described that DILI resulted  in significant overall mortality (17.3 % ).Anti Tuberculous 
Drugs (ATD), anti-convulsants, sulphonamides, and olanzapine were  the leading causes of 
DILI. Although DILI was common in males, more females developed fulminant hepatic 
failure. The principal finding of that series was an overall mortality of 17.3% and 21.5 % 
mortality for anti-TB DILI. ATT was the major cause of DILI accounting for 58 % of cases, 
followed by anti-epileptic drugs, which accounted for 11.2 % of DILI.[17]. Although 
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amoxicillin- clavulinate or penicillin group of drugs are the common drugs in Western series 
(> 50%), in their series four-drug anti-tuberculous agents was the commonest cause. Another 
population-based study from Spain that included 33 cases of anti-TB DILI reported mortality 
of 22.7% [19]. Contrary to earlier reports this study did not show old age or female gender as 
risk factors for DILI.In another study published form AIIMS, Ramesh Kumar et al concluded 
that ATT-ALF constituted 5.7% of ALF at their centre and was associated with a high 
mortality rate [15]. Because the mortality rate was so high, determining which factors are 
predictors is less important. A high proportion of patients had consumed ATT empirically, 
which could have been prevented. Singla R et al in their study had concluded that older age, 
poor nutritional status including baseline hypoalbuminaemia were independent predictors of 
occurrence of anti-TB DILI.[20] 
 
Causality assessment of drug induced liver injury 
                     DILI is always a differential diagnosis for work up of patients with jaundice or 
abnormal LFT.Causality assessment of DILI can be difficult as there are no specific 
diagnostic markers or tests. Mostly it is the temporal association and course of the liver tests 
after withdrawal of drug that helps in the diagnosis. Exclusion of other aetiologies is also 
equally important. There are many prospective registries in the West. The first model for 
DILI causality assessment was prepared by the Council for International Organisation of 
Medical Sciences (CIOMS)-known as the Roussel Uclaf Causality Assessment Model 
(RUCAM) [21]. The RUCAM was initially tested in a case control study with positive 
rechallenge as cases. The authors finally chose a cut off of 5 and excluded rechallenge as it 
was a part of the case definition. The sensitivity, specificity, positive predictive value and 
negative predictive value were 86%, 89%, 93% and 78% respectively. Another scoring 
system developed by two Hepatologists from Portugal was Maria &Victorino Score which 
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was named after them. [22] But it is more stringent, specific and requires a positive 
rechallenge which can be detrimental sometimes. The RUCAM scoring system which is 
validated and used more frequently including the present study is mentioned below 
   RUCAM(CIOMS) Causality Assessment of a Drug in a case of Drug Induced Liver 
Injury 
1 Enzyme pattern       Hepatocellular                Choleststic or mixed  
Exposue                           Initial      Subsequent      pts        Initial     Subsequent     pts 
Time from drug start(d)   5-90           1-15              +2 
                                     <5or>90       >15               +1 
Time from drug stop(d)  ≤15              ≤15              +1 
        5-90        1-90               +2 
      <5or>90     >90               +1 
        ≤30          ≤30               +1       
2 Course           Difference between- peak ALT and ULN 
After drug stop    Decrease ≥50%in 8d                     +3 
                           Decrease ≥50%in 30d                   +2 
                           Decrease ≥50%in> 30d                  0  
                           Decrease<50%in> 30d                  -2  
-peak ALP/bilirubin and ULN 
Decrease ≥50%in≤ 180d        +2 
Decrease<50%in< 180d         +1  
Persistence/increase/no info     0   
3 Risk factor    Ethanol: yes                                      +1 
                     Ethanol: no                                         0    
Ethanol/pregnancy:yes          +1 
Ethanol/pregnancy:no             0 
Age                   ≥55                                                                                                   +1 
                         <55                                                                                                     0 
4 Other drugs None or no information                                                                             0 
Concomitant drug with compatible time to onset                                                         -1 
Concomitant drug known as hepatotoxin and with compatible time to onset                -2             
Concomitant drug with e/o of its role in this case (+ve rechallenge or validated test)      -3         
5Competing causes:Group1:Recent HAV,HBV, 
HCV,biliary obstruction,alcohol,recent hypotension, 
 GroupII:complications of underlying disease,clinical or 
biological context suggesting CMV,EBV or herpes virus 
infection. 
All causes of GrI/II ruled out   +2 
The 6 causes of GrI ruled out  +1 
5or 4 causes of GrI ruled out      0 
<4causes of GrI ruled out          -1
No drug cause highy probable  -3 
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6 Previous information on hepatotoxicity of the drug 
Reaction labelled in the product characteristics   
Reaction published but unlabelled        
Reaction unknown 
                                                
                                           
                                            +2 
                                                             +1
                                                               
                                                               0 
7 Rechallenge  Positive                                             +3 
Compatible                                                             +1 
Negative                                                                  -2 
Not done or not interpretable                                   0 
Positive                                     +3 
 
Compatible                               +1 
 
Negative                                   -2 
 
Not done or not interpretable    0 
  
Causality assessment model of RUCAM 
Highly probable Score >8 
Probable                               score6-8 
Possible score 3-5 
Unlikely score 1-3 
Excluded score≤0 
   
                         Even after defining causality assessment models there are several limitations. 
These are not popular in paediatric DILI and routine use is not recommended. The 
classification of the injury into hepatocellular, cholestatic or mixed depends on the value of 
alkaline phosphatase which is highly variable in growing children [23].They use medicines 
less frequently than adults. Assessing causality in patients with underlying chronic liver 
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disease is intrinsically more difficult. Also when multiple drugs are involved it is often 
difficult to point out one single agent as the causative agent. 
 
Metabolism of Drugs and Mechanisms in drug induced liver injury  
            The liver metabolizes virtually every drug or toxin introduced in the body. Most drugs 
are lipophilic.There are three phases in drug metabolism. Phase 1reaction involves oxidation 
or hydroxylation of the drug/metabolite which can result in toxic intermediates, e.g.  -the 
metabolite of acetaminophen is N -acetyl-p-benzoquinone-imine (NAPQI).This is mediated 
via - CYP-450 enzymes ,located in the  smooth endoplasmic reticulum. At least 50 enzymes 
have been identified which grouped into10 of which groups 1, 2, and 3 are being the most 
important in drug metabolism. Phase 2- occur within or outside the liver. They involve 
conjugation with a moiety (i.e., acetate, amino acid, sulphate, glutathione, glucuronic acid) to 
facilitate excretion from the hepatocyte.Drugs with high molecular weight may be excreted in 
bile and the kidneys excrete the smaller molecules.Phae 3 is a energy-dependent process in 
which parent molecule, or its metabolites, or conjugates are transported into bile [1] 
                The initial process in the pathophysiology of DILI is the disruption of the 
hepatocyte. Covalent binding of the drug metabolites results decrease in ATP levels, leading 
to actin disruption. Disruption of the transport proteins in canalicular membrane can results in 
interruption of bile flow. Interruption of transport pumps (MRP-3) prevent the excretion of 
bilirubin .Cytolytic T-cell activation results in multifaceted immune response and apoptosis 
of hepatocytes [24] . This results in mitochondrial permeability transition which leads to 
inhibition of beta-oxidation resulting in decreased ATP production. TNF apha-trigger the 
cascade of intracellular caspases 3, 6 ,7 and 9 resulting in apoptosis. Toxic metabolites 
excreted in bile may cause injury to the bile duct epithelium also [25]. 
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             There are two types of DILI -1) Intrinsic or predictable drug reactions, 2) 
Idiosyncratic (metabolic idiosyncratic and Immunoallergic) drug reactions. The classic 
example of dose related and predictable DILI is acetaminophen. In this liver injury  occurs 
after a short latent period (hours) and is characterized histologically by zonal necrosis or 
microvesicular steatosis.Idiosyncratic metabolic drug injury is defined as the susceptibility of 
rare persons to hepatotoxicity in conventional doses which is usually safe. This results from 
genetic or acquired differences in drug metabolism or canalicular secretion, mitochondrial 
defects, or cell death receptor signalling pathways. Here the latency varies from 7 days -1 
yr.In Immuno allergic type, the immune system mediates the response to a drug. It is 
characterised by fever, rash, and eosinophilia and short latency period of 1-4 weeks E.g.: 
Phenytoin.  
 
Risk Factors for drug induced liver injury 
1) Genetic Factors-Atopic patients are at increased risk of drug induced hepatitis.Many 
genetic factors determine the drug-activating and antioxidant pathways, encode pathways of 
canalicular bile secretion and modulate the immune responses, tissue stress responses, and 
cell death pathways. Familial predisposition to adverse hepatic drug reactions has been 
reported (e.g -valproic acid and phenytoin ) .Inherited mitochondrial diseases  are risk factors 
for valproic acid–induced hepatotoxicity .Pattern of liver injury could be influenced by 
genetic determinants. Class II HLA haplotype is linked to cholestatic or mixed liver damage 
for some drugs like Amox-clav and Ticlopidine. 
2) Age-DILI is more common in adults than in children, the exceptions being valproic acid 
(<3yrs), Reye's syndrome. Hepatotoxicity due to INH, Mox-clav, Halothane, Diclofenac, and 
Troglitazone are reported to be  more in people who are above 55 yrs. Also in older age  
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cholestatic or mixed patterns of DILI are said to be more common.[6] DILI cases in children 
are generally mild, but  paediatric DILI patients have the potential to progress to ALF. 
3) Gender -Conflicting results have been reported in various studies. Some studies have 
shown an increased risk in females especially with drugs like Nitrofurantoin, Diclofenac, or 
Minocycline .But as recent review found that female sex was not a specific risk factor for 
developing DILI [26]However it has been observed that  females are prone for  hepatocellular 
pattern of DILI and hence a worse outcomes including ALF  and higher mortality [27]. 
4) Concomitant exposure to other drugs-Patients taking multiple drugs are more likely to 
experience an adverse reaction than those who are taking one agent. Cytochrome P450 -
mediated metabolism of the drugs results in multiple toxic intermediates. And these alter the 
disposition of drugs by reducing bile flow or competing with canalicular pathways for biliary 
excretion.  
5) Previous  drug reactions-Increases the risk of reactions to the same drug and also to some 
other agents. Previous reaction to the same drug is a major risk factor for  severe DILI. Cross-
sensitivity between drugs are also reported, e.g. haloalkane  anesthetics, erythromycins, 
phenothiazines  and TCA,INH and PZA, sulfonamides and  some NSAIDs. 
6) Alcohol-Increases the risk and severity of Acetaminophen,INH, Niacin  hepatotoxicity, 
and Methotrexate  induced hepatic fibrosis 
7)Nutritional status- Obesity  increases the risk of halothane hepatitis, NASH and hepatic 
fibrosis in persons taking methotrexate or tamoxifen .How ever there is no indication that 
body mass index (BMI) has significant influence on the risk, pattern, severity, or outcome of 
DILI [27] Some Indian studies have shown malnutrition as a risk factor for INH 
hepatotoxicity [20]. 
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8) Pre-existing liver disease-Pre-existing liver disease is a critical determinant ofMethotrexate 
induced hepatic fibrosis .Chronic hepatitis B and HCV infection or HIV/AIDS increases the 
risk of liver injury during ATT, HAART therapy, NSAID, Myeloablative therapy, anti 
androgens.[28] 
Patterns of DILI  
                     The    patterns of drug induced liver injury is divided into 3 categories based on 
the recommendations of the Council for the International Organisation of Medical 
Science(CIOMS) namely-hepatocellular ,cholestatic and mixed [21].Most of the patients 
presenting with hepatocellular DILI tend to be younger and a higher incidence of  ALF was 
observed  and hence Liver transplantation was offered to them frequently ,where as those 
with  choleststic/mixed pattern tend to be older age group in whom it was precluded because 
of many reasons. However, in a prospective study conducted by Ibanez et al, similar case 
fatality was observed in acute hepatocellular and cholestatic liver injury [29]. 
 
CIOMS consensus criteria for terminology in drug induced liver injury[21,30] 
Terminology Criteria 
Hepatocellular injury Isolated increase in ALT > twice normal or ALT/ALP≥5 
Cholestatic injury Isolated increase in ALP>twice normal or ALT/ALP≤2 
Mixed injury ALT and ALP are increased and 2<ALT/ALP<5 
Acute injury  Above changes present for <3 months 
Chronic injury Above changes present for >3 months 
Chronic liver disease  This term is used only after histologic confirmation 
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Prognosis in acute  drug induced liver injury (DILI) 
            Hyman Zimmerman, the pioneer in DILI studies observed that the combination of 
hepatocellular injury associated with jaundice was associated with a mortality rate of 10%-
50% for different drugs involve. Hy’s rule is defined as a DILI with serum alanine 
aminotransferase (ALT) greater than 3 times the upper limit of normal along with s.Bilirubin 
more than 2 times the upper limit is associated with mortality of more than 10% [3].This was 
accepted by the US FDA for monitoring hepatotoxicity in clinical trials. The Hy’s rule has 
been validated in different studies. Andrade et al observed mortality of 11% in patients with 
hepatocellular injury and jaundice [31].Devarbhavi H et al noted mortality of 26% in patients 
with DILI and icterus. [17] 
 
                    The majority of patients with symptomatic acute drug induced liver injury (DILI) 
are expected to completely recover with supportive care after cessation of the offending drug. 
Milder episodes of DILI that may be unrecognized. It is also expected that these patients 
recover without residual clinical, laboratory, radiological, or histological evidence of liver 
disease. Even in presence of icterus majority of patients will recover clinically.  However, the 
prognosis of patients with severe DILI who progress o acute liver failure (ALF) with 
coagulopathy and encephalopathy is usually poor. In most Western countries, acetaminophen 
overdose is the most frequently identified aetiology of ALF. But the prognosis is generally 
better in acetaminophen-induced liver failure patients treated with N-acetylcysteine than in 
ALF patients with idiosyncratic DILI (i.e., 60 to 80% versus 20 to 40%, respectively, in the 
absence of transplantation.). In the largest prospective series of U.S. ALF patients with 
idiosyncratic DILI, only 25% recovered once encephalopathy developed [16]. In the same  
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study, only advanced degree of encephalopathy at admission predicted mortality where as age 
,sex and ethnicity were not. Recently, the U.S. Acute Liver Failure Study Group 
demonstrated that intravenous N-acetylcysteine therapy may benefit patients with ALF due to 
DILI, hepatitis B, and other aetiologies, particularly in those with early-stage encephalopathy 
[32]. But empiric use of corticosteroids in ALF due to DILI is not recommended due to the 
lack of benefit in previously reported studies. In view of poor prognosis, all patients with 
severe DILI should be referred to a centre with liver transplant facility. Age, bilirubin, 
aspartate aminotransferase (AST), and prothrombin time have been proposed as predictors of 
mortality.  Bjornnson et al concluded age, AST, and bilirubin as independent predictors of 
poor outcome [33].O’ Grady et al. reported the association of increased age, bilirubin, and 
coagulopathy with poor outcome in a small number of patients with idiosyncratic non-
paracetamol, non-halothane DILI patients with fulminant hepatic failure [34].  
 
Role of liver biopsy in DILI 
           
                 The role of liver histology in the diagnosis and management is unclear. It may be 
useful in the setting of positive auto antibodies and persistently abnormal LFT.There is no 
pathgnomonic hall mark in histology. Certain histologic patterns can suggest DILI.These 
include zonal necrosis ,micro vascular steatosis,mixed hepatocellular and cholestatic pattern, 
disproportionate necrosis as compared to clinical picture, destructive bile duct lesions, 
prominent neutrophils and eosinophils(>25% of inflammatory cells),and hepatic granuloma 
formation [35].Severe hepatic necrosis is associated with 85% mortality. Studies have found 
that both peripheral and hepatic eosinophilia on biopsy are associated with a favourable 
outcome [19] 
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    Anti Tuberculous drug  induced liver injury(anti-TB DILI) 
 
                        Despite progress in antimicrobial chemotherapy over the past 50 yrs, 
tuberculosis (TB) remains a major cause of illness and is the greatest infectious cause of 
death worldwide. Globally a total of 9.2 million new cases and 1.7 million cases of deaths 
from TB were reported in 2006 [36].World Health Organization estimated that prevalence of 
TB in India was 299 per 100,000population accounting for about one fifth of global figure. 
Mortality from TB in India is 28 per 100,000 population making it a major public health 
issue.ATT DILI is generally defined as a rise in ALT or AST more than five times the upper 
limit of normal in any patient or more than twice the upper limit of normal in the presence of 
symptoms or s.bilirubin more than twice the upper limit of normal in any patient taking 
hepatotoxic ATT regimen [18, 37, 38]. 
                         With modern anti-tuberculous treatment plus directly observed therapy, short 
course (DOTS),more than 85% detected cases of TB can be successfully treated. However 
treatment related adverse events are commonly encountered, especially within the first few 
weeks of therapy and anti-tuberculous drugs are one of the commonest groups of drugs that 
results in idiosyncratic hepatotoxicity world wide[16,39,40].The most frequent side effects of 
anti tuberculous treatment are hepatotoxicity, skin reactions, gastro intestinal and 
neurological disorders [41].Analysis of data from US FDA calculated that death rate among 
subjects receiving INH preventive therapy was 23.2 per 100,000 persons. Frequency of DILI 
from anti –TB medication is higher in Indian subjects compared to Western countries [15,42] 
         
                       The number of cases of TB has increased dramatically in the past decade, 
especially in case of multi drug resistant strains. This has led to the use of combination 
therapy which consists of an initial induction phase of four drug viz, INH, rifampicin(RIF),  
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pyrazinamide (PZA), and ethambutol(ETH)  for 2 months followed by a continuation phase 
of INH and rifampicin for 4 to 7 months. The first three drugs (INH, RIF, PZA) are 
bactericidal where as the last one (ETH) is bacteriostatic.Hepato-toxicities of the first three 
drugs are well documented. A meta analysis of ATT associated hepatotoxicity reported that 
the frequency of clinical hepatitis caused by INH, rifampicin, or both together was 0.6%, 
1.1%, and 2.6%, respectively.  
                        These spectrums of ATT hepatotoxicity is diverse, ranging from asymptomatic 
rise in aminotransferases in2.3% to 28% to acute liver failure (ALF) in approximately fewer 
than 0.01% of the individuals. There is a wide variation in incidence of ATT DILI in India in 
different studies as well as in the West (8%-30%) [43,44].In a recent study from Bombay 
Agal S et al showed the incidence to be 10.5% in their study population [18].Similar result 
was also published by Anand AC et al in another study [45].In an analysis of pooled data 
from four Indian studies ,the risk of clinical hepatitis due to anti tuberculosis drugs is 
estimated to be 11.5%.[20] .Bose PD,et al has reported the incidence of anti –TB DILI to be 
18.8% in a recent study conducted in Delhi in patients with pulmonary TB[85].A meta 
analysis of studies from the West has shown it to be 4.28%( 95% CI 3.38-5.28).The higher 
incidence of anti-TB DILI in Indian subjects may be as a result of genetic susceptibility, 
inherent peculiarity of drug metabolism ,under nutrition, or the presence of multiple risk 
factors like HBV/HIV infection. Also acute viral hepatitis is an important mimic of DILI in 
terms of clinical, biochemical and histological presentation. Sarda P et al has noted that acute 
viral hepatitis can complicate anti TB treatment in up to 14.7% of patients on ATT, in 
countries like India where hepatitis E virus infection is endemic [46].In a prospective study 
from a tertiary care hospital in North India, Singh J etal reported ATT –ALF in 9.7% of their 
study population of 72 patients and the mortality was 85.7%.[82].It has higher mortality than 
hepatitis due to hepatotropic viruses.  
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                 In other parts of the world also similar incidence is reported. A study conducted at 
a tertiary hospital in Iran has shown the incidence of anti-TB DILI to be 13% and mortality 
was about 13%.It occurred most frequently in the first 2 weeks of treatment and higher rate 
was noted in the elderly patients [47].A multi centre study conducted in Nepal identified that 
about 15% of DILI was due to ATT [48].In a nationwide survey of severe anti TB DILI in 
Japan ,the incidence was 0.50 to 0.59 % in three hospitals with good surveillance system and 
the overall incidence was 0.1% to 0.5% in the total study population. But 8 out of 29 patients 
(27.5%) died due to liver failure. Majority of these patients were on ATT for 2 months. 
Although they could not identify any specific risk factor for DILI, a higher bilirubin 
(>5mg%) was associated with poor outcome [49].In a prospective study of anti- TB DILI 
from Egypt( country which is endemic for liver diseases),the incidence was 15%.The 
majority of patients had DILI within one month of start of therapy. It was also noted that re 
introduction of pyrazinamide was associated with a fatal outcome [50].Nash KL, has reported 
a case of sub acute liver failure due to anti TB treatment which was successfully treated with 
orthotopic liver transplantation [51].Singh J etal, reported 4 cases of SAHF from North 
India[82].In another study from UK ,Wendon J et al has described successful orthotopic liver 
transplantation in 3of 4 patients of ALF due to anti-TB DILI referred to their centre[52].The 
prognosis in ATT ALF is extremely poor (less than 20% survival ) and hence early referrel 
for liver transplantation is indicated. 
                                   In a recent study published from France, P.Ichai et al reports that ATT 
induced ALF contributed to2.8% of patients referred for liver transplant in the study period of 
22 yrs [53].In another retrospective analysis of the data from the United Network for Organ 
Sharing Registry(UNOS),during the period of 1987-2006,0.07% of liver transplantation were 
for ALF due to anti-TB DILI.Majority of these cases were due to INH ,rest being caused by 
pyrazinamide and rifampicin [53].In a  recent study from AIIMS ,ATT induced ALF 
constituted 70 of 1223 (5.7%) consecutive ALF patients admitted there over a period of 23 
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yrs [15].Most of the guidelines do not recommend routine monitoring of LFT in patients on 
ATT except in the setting of underlying CLD or other risk factors. In a prospective study 
conducted by S Agal etal ,they found that those patients who were on regular LFT monitoring 
while on ATT did not develop liver failure because ATT was promptly stopped when 
transaminits occurred .In those(control group) who were not on regular monitoring, many 
patients developed icteric hepatitis, of which a significant proportion developed liver failure 
requiring  ICU care[18].  
  
Pathogenesis of anti -TB DILI 
 
                        Pathogenesis of anti-TB DILI is not well understood. Histopathological 
evidence resembles that of viral hepatitis-namely hepatocyte necrosis, ballooning 
degeneration, and inflammatory infiltrates. Although these can resemble dose related 
hepatotoxicity there is no direct relation between serum drug level and the degree of 
hepatocyte necrosis[54].Even though  there are no sentinel features of reactive metabolite 
syndrome, the presence of eosionophils on liver biopsy as well as the recurrence of 
hepatotoxicity on re challenge indicates idiosyncratic hypersensitivity as a possible 
mechanism. Continuation of INH despite symptoms has been associated with a severe 
clinical course and fatal outcome. However compared with INH, DILI caused by Rifampicin 
occurs earlier .Histologically it is characterised by patchy hepatocyte necrosis with peri portal 
inflammation. It may occur as a part of systemic allergy response .Unconjugated 
hyperbilirubenemia can occur due competitive uptake with bilirubin. Even bridging necrosis, 
fibrosis and micro nodular cirrhosis have been reported in patients who died of rifampicin 
and pyrazinamide induced hepatotoxicity [41,55] The exact mechanism of DILI due to 
pyrazinamide is not known. It generally produces delayed hepatotoxicity, but this is not 
always the rule.INH is often associated with fulminent liver failure whereas pyrazinamide 
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often leads to sub acute hepatic failure. Significant transaminitis is reported in0.5% of 
patients on INH monotherapy, 1-2% of patients on Rifampicin prophylaxis. The risk 
associated with pyrazinamide in its current dosage is not known. But it was recently reported 
that it causes more hepatotoxicity than INH or rifampicin [41]  
 
 
Metabolism and mechanisms of anti-TB DILI 
 
Isoniazid 
                   Isoniazid was first used in 1950s.It carries 20% risk of biochemical hepatitis 
although overt hepatitis is much lower [56]. Although both metabolic and immunologic 
factors are likely to be involved in DILI, investigation thus far has been focussed on the 
metabolic pathway of INH. The enzyme N-acetyltransferase (NAT) is responsible for the 
metabolism of INH to acetyl isoniazid which in turn is hydrolysed to acetyl hydrazine. The 
latter could be oxidised by CYP2E1 to from N-hydroxy-acetyl hydrazine, which further 
dehydrates to yield acetyl diazine. Acetyl diazien may itself be the toxic metabolite or may 
break down to reactive acetylonium ion ,acetyl radical, and ketene, which could bind  
covalently with hepatic macro molecules resulting in liver injury.NAT is also responsible for 
further acetylation of acetyl hydrazine to non toxic diacetyl hydrazine. Therefore, slow 
acetylation results not only in accumulation of the parent compound but also of monoacetyl 
hydrazine. Acetylation of acetyl hydrazine is further suppressed by INH itself. In addition, 
direct hydrolysis of INH without acetylation produces hydrazine that could cause liver injury. 
Liver biopsy usually shows necrosis with marked inflammatory activity which is the classic 
finding in idiosyncratic DILI [30]. 
 
Rifampicin 
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                            Rifampicin was introduced as first line anti TB treatment in 1960s.It 
undergoes desacetyaltion into desacetyl rifampin and on hydrolysis produces 3 –formyl 
rifampicin. Although rifampicin results in hepatocellular dysfunction early in the course, it 
can resolve spontaneously. There is no evidence of presence of any toxic metabolite and the 
mechanism of toxicity is largely unknown. The combined use of rifampicin with INH is more 
hepatotoxic since it is a potent inducer of CYP 450 enzyme system and also induces isoniazid 
hydrolase. Rifampicin causes transient elevation in hepatic enzymes usually in the first 8 
weeks of therapy, but only in, 1% patients it presents as overt hepatitis [57]. 
 
Pyrazinamide (pyrazoic acid amide-PZA) 
                           It is converted into pyrazinoic acid and the oxidised to 5(OH) pyrazinoic 
acid by xanthine oxidase. It is unknown that the drug itself or its metabolite produces 
toxicity. In animal models pyrazinamide has shown to inhibit different CYP 450 systems, but 
it is not documented in humans.PZA has a longer half life of about 10 hrs which is 
significantly increased in patients with underlying liver disease (up to 15 hrs).It can exhibit 
both dose dependent as well as idiosyncratic injury. Allopurinol along with PZA can be 
hepatotoxic because it can inhibit xanthine oxidase which is essential for the clearance of 
PZA. In studies done by Singh A et al , pyrazinamide even in lower doses is found to be 
hepatotoxic. 
                         In general reactive metabolites formed during the biotransformation of drugs 
generate intra cellular oxidative stress which in turn induces mitochondrial membrane 
permeability transition.(MPT).The cellular consequence of MPT is loss of membrane 
potential that is required for ATP synthesis which ultimately leads to hepatocyte death mainly 
by necrosis[58].However drug metabolites simultaneously activate both injurious and 
protective pathways. The threshold for hepatocyte death can be modulated by intra cellular 
signal transduction and transcription factors for protective((NF E2 related factor 2-NRF2)  
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and injurious (c-Jun N-terminal Kinase-JNK)pathway [59].It is plausible that the balance 
between the activation of protective and injurious pathway may  determine the clinical effects 
of reactive metabolite.NRF2 regulates glutathione synthetic and detoxification enzymes and 
NRF2 directed endogenous anti oxidant systems in the liver may dampen the injurious effect 
of reactive metabolites and lead to what is clinically recognised as “adaptation” .On the other 
hand if the oxidative stress is sufficiently high, it may overwhelm this anti oxidant system 
leading to serious DILI 
      
                       In macrophages, it has been proposed that there exists a hierarchical response 
to oxidative stress [59].At low oxidant levels cells adapt to the stress by inducing a cyto-
protective gene battery, comprising anti oxidant proteins, drug metabolising enzymes, heat 
shock proteins, and 26 s proteosome sub units in which the responsive genes each contain an 
antioxidant response element (ARE) in their promoters. The principle ARE containing anti 
oxidant genes that are induced by NRF2 include those for the glutamate cysteine lygase 
catalytic (GCLC) and modifier(GCLM) sub units, that catalyse the rate limiting step in 
glutathione biosynthesis as well as glutathione reductasse, thioredoxin,thioredexin reductase, 
peroxiredoxins,ferritin, metallothionine , and heme oxygenase 1.Recent investigations have 
demonstrated that activation of NK/NKT cells, major components of resident lymphocytes in 
the liver, play an important role in DILI. Intracellular stress of reactive metabolites activates 
both pro and anti inflammatory cascades which modulate the progression of liver injury into 
adaptation of serious DILI. 
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Risk Factors for anti-TB  DILI 
 
1) Demographic Factors -Advanced age (>60yrs), female sex, low BMI, low mid arm 
circumference, malnutrition are shown to increase the risk of ATT DILI [60-63].In one study 
it was found that anti-TB DILI in children was more common under age 5yrs,extra 
pulmonary TB and with the use of PZA. In a South Indian study TB DILI in children was 
noted in 16%-39% of TB meningitis patients. However no significant relation between BMI 
and risk of anti -TB DILI was noted in a study published by Anand AC etal[45].Also another 
study from India by Thiagu R et al did not find any statistically significant difference 
between males and females [64].Older patients have altered metabolism of drugs due to 
decreased levels of CYP 450 enzymes and  the effect of con concomitant multiple drugs. 
There is also change in the hepatic blood flow as well as the volume of distribution. Females 
have a higher level and activity of CYP 3A and hence are at higher risk. Malnutrition results 
in poorer xenobiotic clearance and hence higher plasma levels.Singla R et al in a recent study 
has observed hypoalbuminemia (albumin<3.5g/gL)  and malnutrition as predictors of anti-TB 
DILI[20]. 
  
2) HIV/AIDS- HIV infection increases the risk of DILI due to standard multidrug treatment. 
They have altered activities of oxidative pathways which might explain the cause.Also 
concurrent therapy with anti retroviral drugs results in over lapping toxicities and drug-drug 
interactions.. The incidence of DILI in anti retroviral treatment ranges from 2%-18%.It has 
been observed that HIV positive patients develop less hepatotoxicity compared to negative 
patients when rifampicin or pyrazinamide were given for treatment of latent tuberculosis[41]. 
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3)Underlying liver disease.-Many studies have shown that Hepatitis B or C increase the risk 
of ATT DILI .One report from Taiwan has shown that ATT induced fulminent and sub acute 
hepatic failure were more common in the HBsAg carrier group. In general patients with 
underlying liver disease are at risk of DILI. However Lee BH et al  have shown that ATT can 
be given safely as in the short course regimen in HBsAg positive and HBeAg negative in 
active carriers without any added risk, provided monthly LFT is done[65]Another study by 
Kaneko et al has shown that INH and rifampicin without PZA  can be safely given in patients 
with chronic hepatitis[66]. 
 
4)Genetic risk factors-The genetic polymorphisms in different metabolising enzymes can 
alter the activity of enzymes and hence predispose one for DILI.T his may be because of 
different rate of formation of drug metabolites or adducts. Recently lots of data have come up 
on DILI and genetic risk factors. The proposed risk factors for anti-TB DILI are slow 
acetylators(without the NAT*4 allele),CYP P4502E1 homozygous wild type, Human 
Leukocyte Antigen  DQ null mutations and the glutathione S –transferase homozygous null 
type(GSTM1).This can explain the different risk in various population[67-69].Hence regular 
monitoring of amnotransferase is important in patients receiving anti tuberculous treatment in 
case of slow acetylator [70].How ever in a study done by Singh J et al no significant 
difference was noted among slow or rapid acetylatiors in anti-TB DILI[71]. Severe DILI 
cases have shown to carry low or intermediate IL-10 producing haplotype and it was 
phenotypically expressed as low or normal eosinophils in peripheral blood[72].The role of 
genetic polymorphisms in Indian patients with anti-TB DILI i9s not well studied. Bose PD,et 
al has observed that NAT-2 slow acetylator genotypes to be significantly more in anti TB 
DILI patients than controls. They also observed a possible association between 
Dra1polymorphism of the CYP2E1 gene and risk of anti-TB DILI [85]. 
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5) Intoxications- Alcohol can induce hepatic enzymes and hence is associated with a higher 
incidence of ATT DILI. 
6) Dosing schedule- Several studies have shown that thrice –weekly regimen has less of 
hepatotoxicity than daily regimen [73].But recent studies have shown that it not true [74].In a 
study conducted at New Delhi Dhingra et al observed that the incidence of ATT DILI in 
DOTS therapy was significantly low –one out of 1195 patients [75] while a Hong Kong trial 
reported the rate to be  2%[76]. 
 
Management of anti-TB DILI    
 
          Several guidelines have been proposed by American Thoracic society (ATS), British 
Thoracic society(BTS),WHO and the Task Force for European respiratory Society[37 
,38].The first step is stopping the anti TB drugs when DILI is suspected. TB should be treated 
under the supervision of a qualified physician. They should seek medical attention when 
symptoms of hepatotoxicity develop viz, malaise, nausea, vomiting and jaundice. Regular 
monitoring of LFT is recommended in patients who have underlying chronic liver disease or 
increase in transaminsae prior to treatment [37].The treatment should be stopped if the 
transaminsases are elevated more than 5 times the upper limit of normal in the absence of 
symptoms, more than 3 times the upper limit in presence of symptoms or if bilirubin is more 
than 2 mg%. Asymptomatic transaminits can occur in up to 20 % of patients during anti TB  
treatment which can resolve spontaneously due to hepatic adaptation.ATS does not 
recommend baseline liver function test except in high risk patients where as the BTS and 
Task force recommend routine baseline LFT in all patients. Once TB treatment is stopped 
because of DILI, both ATS and BTS advocate for sequential reintroduction of drugs where as 
the Task Force advises all drugs simultaneously. A recent report published by Sharma SK et  
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al concluded that all the three different regimens were equally effective without higher risk  
although the arm which was started on full dose ATT had a mild increase in recurrence which 
was not statistically significant [77].The pre treatment albumin was the only statistically 
significant predictor of future recurrence of DILI. 
                        In many developing countries the burden of TB is very high and routine 
monitoring by LFT cannot be recommended. In such situations the patient should be taught 
about the symptoms of hepatotoxicity and their presence should lead to prompt evaluation of 
LFT. Many patients have undergone successful liver transplantation after severe anti-TB 
DILI and they could be successfully restarted on anti TB treatment after  transplantation 
[51,52] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Monitoring for hepatotoxicity during treatment of TB disease. Adapted from ATS 
guidelines.[37] 
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 Future Directions 
              The mechanisms of TB DILI are still largely unknown. Further studies on genetic 
polymorphisms of enzymes involved in drug metabolism is required to identify patients who 
are at risk of ATT DILI.Truly ‘predictive biomarkers’ can reliably identify patients, in whom 
exposure to a specific drug can be avoided. As the balance of injurious vs anti oxidant 
pathways determine the evolution of mild injury secondary to a reactive metabolite into an 
‘adaptation’ or serious DILI,many studies are aimed to develop  an optimal combination of 
products of oxidative stress, cellular response and cytokines that modulate the inflammatory 
response  as biomarkers  that would help to distinguish adaptation from serious DILI. One 
such approach is metabolomics which focuses on broad identification and analysis of 
multiple metabolites simultaneously. Recent human clinical trials of drugs, have shown that 
the metabonomics of bio-fluids collected before and immediately after dosing can identify 
individual patients who are likely to develop DILI. It is said to be complimentary to or 
potentially superior to genetic testing for identifying risk in DILI. Another area of research is 
Transcriptomics which is aimed at identifying liver derived mRNAs in the cell free plasma in 
patients with DILI. Proteonomics involves identifying protein biomarkers in patients with 
DILI (e.g,Cytokines).Another test commercially available and used in Japan is the 
lymphocyte transformation test which involves culturing of the pateint’s lymphocytes in the 
presence of suspected drug.In positive test there is proliferation of lymphocytes which can be 
measured in several ways. DILIN network is doing ancilliary study to critically assess the 
value of this test. 
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                 Materials and methods 
 
                             The present study is a case control study which is partly retrospective and 
partly prospective. Consecutive patients with anti tuberculous treatment induced liver failure 
admitted in the department of Clinical Gastroenterology and Hepatology, Christian medical 
college, Vellore from January2006 to January 2011 were studied. Those patients who 
attended the Liver clinic or Medicine III OPD with asymptomatic or symptomatic anti 
tuberculous treatment induced hepatitis from January 2009 to January 2011 were taken as the 
controls. Consent to include in the study and analysis was taken from the patient or nearest 
relative in all the prospectively studied patients. The study protocol was approved by the 
Institutional review board. 
 
Inclusion Criteria  
  Cases- All patients of anti-TB DILI (ie, those who are on one or more of the first line 
hepatotoxic anti tuberculous drugs-INH, Rifampicin or Pyrazinamide) with liver failure 
(acute liver failure and sub acute hepatic failure). Causality assessment was made using the 
RUCAM score (Russel Uclaf Causality Assessment Model).Those with a score of >5 were 
included. 
Controls-Patients on anti tuberculous treatment that includes any regimen containing 
Isoniazid, Rifampicin or Pyrazinamide who have symptomatic or asymptomatic transamintis 
without any evidence of liver failure. 
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Exclusion criteria  
 
• All cases of TB DILI with RUCAM score less than ≤5. 
• Patients on non hepatotoxic ATT regimen. 
• Patients with acute viral hepatitis while on ATT.  
• Patients who failed to give consent. 
 
 
Study variables 
Acute Liver Failure (ALF)-was defined as presence of jaundice complicated by 
encephalopathy within four weeks of the onset of jaundice in the absence of pre existing liver 
disease.[78] 
 
Sub acute hepatic failure (SAHF)- is a distinct condition defined by the persistence of 
jaundice complicated by hepatic decompensation in the form of ascites and or 
encephalopathy from fifth to twenty fourth week in the absence of pre-existing chronic liver 
disease.[78] 
 
Acute on chronic liver failure (ACLF)- is defined as the acute hepatic insult manifested as 
jaundice and coagulopathy complicated within 4 weeks by ascites and or encephalopathy in a 
patient having diagnosed or undiagnosed chronic liver disease. 
ATT induced hepatitis (AIH)- was defined as  elevation of  serum transaminase (alanine 
amino transferase-ALT and/or aspartate amino transferase-AST) more than 2 times the upper 
limit of normal (ULN) in the presence of symptoms or more than 5 times the ULN in the 
absence of symptoms. The symptoms suggestive of hepatitis are nausea, vomiting, anorexia, 
malaise, right upper quadrant abdominal discomfort, jaundice, and skin rash. 
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Grading of encephalopathy [80] 
 
Grade 1: Personality changes, attention deficits, irritability, depressed state 
Grade 2: Changes in sleep-wake cycle, lethargy, mood and behavioural changes, cognitive 
dysfunction 
Grade 3:  Altered level of consciousness (somnolence), confusion, disorientation, and 
amnesia 
Grade 4: Deep unconscious state, with absence of response to painful stimuli. 
 
                      Renal failure was diagnosed if patients developed decreased urine output (<400 
mL in 24 hours), with serum creatinine greater than 1.4 mg/dL despite hydration, objectively 
assessed by central venous pressure of 10 cm saline or more. 
 
                      Prognostic factors analysed in the present study were grade of encephalopathy 
,S.Bilirubin,  prothrombin time, renal failure (creatinine more than 1.4mg%) ,elevation in 
liver enzymes, ascites,spontaneous bacterial peritonitis, age >35yrs, sex, duration of ATT, 
continuation of ATT despite symptoms, alcohol consumption, underlying chronic liver 
disease or chronic hepatitis,  past history of drug induced liver injury. 
Outcome measured was survival or death/discharge against medical advice.  
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Management protocol 
                              All patients with liver failure (ALF, SAHF or ACLF) were admitted to the 
High Dependency Unit (HDU) or the medical intensive care unit for management and 
monitoring. History was obtained from the patient or the nearest relative. For those patients 
who were admitted before January 2009, retrospective analysis was done from the case 
records in terms of clinical presentation, laboratory vales, management and outcome. 
                            A uniform management protocol was present in the hospital for all patients. 
Those who had encephalopathy were on regular monitoring, antibiotics(after taking blood 
cultures) and antifungal prophylaxis (in case of ALF),stress ulcer prophylaxis, anti coma 
measures( mannitol or lactulose),blood sugar monitoring, and elective ventillatory support in 
case of grade IV encephalopathy. Antibiotics were continued until clinical improvement or 
resolution of any infection.Hemodialysis was used whenever indicated. All hepatotoxic anti 
tuberculous drugs were stopped and non hepatotoxic regimen using ethambutol, quinolones 
were used whenever indicated. Aminoglycosides were routinely not used until liver failure 
resolved. Adverse events such as renal failure, spontaneous bacterial peritonitis, gastro 
intestinal bleed, and death were recorded. Liver biopsy was performed (via Transjugular 
route) under FFP cover whenever diagnostic dilemma/persistently abnormal LFT existed. 
Although liver transplantation was done in this hospital, none underwent the same, due to 
scarcity of cadaveric donors. 
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                 Blood investigation done included LFT at base line including bilirubin, AST, ALT, 
albumin, alkaline phophatase,  gamma glutamyl transpeptidase, prothrombin time, activated 
partial thromboplastin time, renal function test, and ascitic fluid analysis (including protein, 
albumin, cell count and culture). Ultrasonography of abdomen or CECT abdomen was carried 
out in all patients to rule out evidence of chronic liver disease, biliary obstruction and ascites. 
Appropriate tests for autoimmune hepatitis (ANA,Anti LKM antibody) and for Wilson’s 
disease (s.ceruloplasmin, 24 hour urinary copper) were done in the liver failure group when 
ever indicated. 
                                                                                                                                                                              
               Markers of acute viral hepatitis were done in all suspected patients of anti-TB DILI. 
These include IgM (Immunoglobulin)anti-hepatitis A virus((ET-HA-IGMK 
PLUS,Diasorin,S.p.A,Saluggia,Italy),IgMantihepatitiaE(MPDiagnostics,St.Ingbert,Germany),
IgM ant- hepatitis B core antigen and /or hepatitis B surface antigen(ETI-MAK-4 Diasorin 
S.p.A,Saluggia,Italy),and anti hepatitis C virus antibodies(AXSYM HCV Version 
3,Abbot,Wesbaden Germany).Serological testing for HIV1 and 2 were also done in all 
patients of liver failure and majority of patients with hepatitis.(AXSYM 
HIVAg/AbCombo,Abbot,Wesbaden,Germany). Prothrombin time prolongation over control 
was done once in 2 days in every patient. 
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Statistical Analysis 
 
                       Normally distributed continuous variables were expressed as mean(SD),and 
those with skewed deviation were  expressed as median (Range).For analysing the cases and 
controls as well as difference between survivors and non survivors, Fisher’s exact test was 
used for continuous variables and Student’s t-test was used for discrete variables. Factors 
with a predictive value of <0.1 on univariate analysis were taken for binary logistic 
regression analysis and a p value of 0.05 was considered as significant. In patients with liver 
failure, we analysed the factors predicting death by Student’s t-test. We dichotomised the 
variables by drawing a ROC curve and found cut-off and odds ratio for predicting death. 
Odds ratio with 95% confidence interval for each variable is reported. Data were analysed 
using SPSS software version 17.0(SPSS, Chicago, IL) and STATA (version 9.2). 
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                    Results   
 
                           A total of Sixty seven patients who developed features suggestive of drug 
induced liver injury while on anti tuberculous drugs were identified during the study period. 
Four patients were excluded because they did not met the inclusion criteria-3 patients were 
IgM anti-HEV positive and one was IgM anti HBc positive. Hence 63 patients were included 
in the study. 
 
                              Of these, 35(55.5%) patients had features of liver failure in the form of 
either ALF (n=9), SAHF (n=19) or ACLF(n=7).ATT induced hepatitis without liver failure 
was noted in 28 patients(44.4%).The spectrum of the disease in the present study is depicted 
in Figure 1.Two patients in the liver failure group had underlying chronic HBV infection and 
one had chronic HCV infection. Majority of these patients were on empiric anti tuberculous 
treatment (n=28,44%),pulmonary TB  was present in 17(26.9%),and extra pulmonary TB in 
18(28.5%) patients.(Fig.2) .Extra pulmonary TB  included intestinal TB,TB meningitis, TB 
spine and Tuberculous  pericarditis..Majority of patients on empiric ATT were initiated by 
general physicians from elsewhere without proper evaluation and these patients came to us 
for subsequent evaluation following anti-TB DILI. 
 
 
 
 
 
 
 
41 
 
 
 
 
 
 
     Figure 1.Shows the spectrum of presentation in the present study of 63 patients with anti-
TB DILI.  
 
 
 
 
 
 
Anti -TB DILI (Spectrum of disease, n=63) 
Anti -TB DILI with  ALF, n=9(14%)
Anti-TB DILI with SAHF, n=19(30%)
Anti-TB DILI with ACLF, n=7(11%)
Anti-TB DILI with  
HEPATITIS, n=28(44%)
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Clinical profile, laboratory parameters and complications in ALF, SAHF, ACLF and acute 
Hepatitis groups 
                                      The mean age (yrs) and range in different groups namely, ALF, 
SAHF, ACLF and Hepatitis were33.78±19.73 (17-73), 40.47±13.67 (9-58), 51±11.44 (35-65) 
and35.50±17.10 (5-66) respectively. Majority of patients with anti-TB DILI were above 35 
yrs (n=35,55.5%).Females formed the  majority of patients in the ALF(n=5,55.5%) and 
ACLF(n=5,71.4%) groups, whereas males were more common in the SAHF(n=12,63.1%) 
and the acute Hepatitis(n=15,55.35%) groups.  
 
                           Past history of anti -TB DILI was present in 2 patients and they presented 
with ALF.  All the patients (n=63) were on hepatotoxic ATT and the duration of ATT prior to 
presentation varied from 1 week to 52 weeks. Majority of patients in the ALF, SAHF, ACLF 
and acute hepatitis groups were on empiric ATT without any definitive etiological diagnosis. 
Significant alcohol intake was present only in 4 out of 63 patients. Underlying diabetes was 
present in 12 of 63(19%) patients. Three patients had underlying chronic hepatitis (2 - 
chronic HBV and 1- HCV infection) and seven had features of chronic liver disease on 
imaging and /or liver biopsy. Majority of patients who developed live failure were continuing 
ATT in spite of symptoms -5(55.5%) in ALF, 14(73.6%) in SAHF and 6(66.6%) in ACLF 
groups, whereas in the Hepatitis group only 6(21.4%) continued the drug in spite of 
symptoms or deranged LFT. Clinical profile and base line characteristics of different groups 
are represented in table 1. 
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                           Majority of patients presented with jaundice, vomiting, and anorexia which 
were common to all the groups. Hypersensitivity reactions in the form of skin rash/urticaria 
was noted in 8/63 patients. Overall 10 patients in the acute hepatitis group had asymptomatic 
LFT derangement. Ascites was present in 3(33.3%), 19(100%), 6(85.7%), and 2(7%) in ALF, 
SAHF, ACLFand the hepatitis groups respectively. 2 patients in the hepatitis group had 
abdominal tuberculosis and both had exudative ascites with lymphocyte predominance. 
Encephalopathy was the defining symptom in the ALF group (100%) and was present in 
9(47.3%), 5(71.4%) in the SAHF and ACLF groups respectively. The most common 
complication noted was acute renal failure which was present in 9(25.7%) patients in the liver 
failure group followed by spontaneous bacterial peritonitis (n=8, 22.8%).The overall 
mortality in the anti-TB liver failure group was 20 out of 35(57.1%).The mortality in 
different subgroups were 8(88.9%), 8(42.1%), and 4(57.1%),for ALF,SAHF and ACLF 
respectively. One patient in the acute hepatitis group died because of underlying lymphoma. 
The clinical presentations and complications are depicted in table2. 
                     The various laboratory parameters in the different groups with anti-TB DILI is 
represented in table3.The calculated MELD score for the liver failure group is also 
mentioned. In the liver failure group 9 patients underwent liver biopsy (post-mortem or 
elective trans-jugular liver biopsy under FFP cover in cases of diagnostic dilemma.).None of 
the biopsy showed any specific changes. Only 1 patient in the ALF group had liver biopsy 
and it showed extensive macro-vesicular steatosis with mild perivenular hepatocyte 
cholestasis and erythrophgocytosis. Seven patients in the SAHF group underwent TJLB since 
there was a suspicion of underlying chronic liver disease (auto immune hepatitis/overlap 
syndrome, Wilson’s disease, atypical copper associated liver disease).The most common 
finding was extensive bridging necrosis with early fibrosis and marked ductular and 
hepatocyte cholestasis.        
45 
 
Clinical profile and baseline characteristics of anti-TB DILI 
  
 
 
Table1.ALF-acute liver failure, SAHF-sub acute hepatic failure, ACLF-acute on chronic liver 
failure .A/c –acute, CLD-chronic liver disease, and CH-chronic hepatitis.DILI-drug induced 
liver injury. 
Variables                           Liver Failure (n=35) A/c Hepatitis 
(n=28) 
ALF(n=9) SAHF(n=19) ACLF(n=7) 
Age(yrs),mean±SD 
Range 
 
33.78±19.73, 
(17-73)  
40.47±13.67(
9-58)  
 
51±11.44, 
(35-65)  
 
35.50±17.10, 
(5-66) 
 
Females, n (%) 5(55.5%)  
 
7(36.8%)  
 
5(71.4%)  
 
13(46.4%)  
 
Duration of 
ATT(wks) 
8(2-16)  
 
7(1-52)  
 
18(8-40)  
 
4(1-24)  
 
Past H/O DILI 2 0 0 0 
Reason for ATT,  
n (%) 
Pulmonary 
Extra pulmonary 
Empiric  
 
 
5(55.5%) 
0 
4(44.4%) 
 
 
 
2(10.5%) 
7(36.8%) 
10(52.6%) 
 
 
3(42.8%) 
1(14.2%) 
3(42.8%) 
 
 
7(25%) 
10(35.7%) 
11(39.2%) 
Alcohol intake 1 1 1 1 
Diabetes Mellitus 1 4 3 4 
Underlying CLD/CH 0 3 7 0 
Continuation of ATT 
despite symptoms 
5(55.5%) 14(73.65) 6(66.6%) 6(21.4%) 
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Clinical presentation and complications of patients with anti-TB DILI 
 
 
   Variables                              Liver Failure(n=35)  
A/cHepatitis(n=28)
 
    ALF(n=9)    SAHF(n=19)    ACLF(n=7) 
Jaundice (n,%) 9(100) 19(100) 6(85.7%) 17(60.7%) 
Vomiting 6(66.6%) 11(57.8%) 4(66.6%) 18(64.2%) 
Rash 2(22.2%) 1(5.2%) 1(14.2%) 4(14.2%) 
Ascites 3(33.3%) 19(100%) 6(85.7%) 2(7%) 
Encephalopathy 9(100%) 9(47.3%) 5(71.4%) 0 
SBP 1(1.1%) 4(21%) 3(42.8%) 0 
Renal Failure 4(44.4%) 3(15.7%) 2(28.5%) 0 
Mortality 8(88.9%) 8(42.1%) 4(57.1%) 1(3.5%) 
 
Table2.ALF-acute liver failure, SAHF-sub acute hepatic failure, ACLF-acute on chronic liver 
failure. A/c-acute, CLD-chronic liver disease, CH-chronic hepatitis.DILI-drug induced liver 
injury. SBP-Spontaneous bacterial peritonitis. 
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Laboratory parameters in patients with anti-TB DILI 
 
 
Variables                             Liver failure (n=35) A/cHepatitis(n=28)
ALF(n=9) SAHF(n=19) ACLF(n=7) 
T.Bilirubin(mg/dl) 16.5(4.8-32.8) 19(3.4-32)  22.2(1.4-
31.5)  
2.9(0.4-14)  
ALT(IU/L) 550(91-946) 77(24-386)  
 
150(58-309)  129(45-564)  
 
AST(IU/L) 461(91-1116) 
 
114(52-349)  
 
139(55-599)  
 
105(19-551)  
 
Alk.Phosphatase(IU/L) 169(134-454) 191(59-688) 131(92-352) 113(58-593) 
S.Albumin(g/dl) 2.55±0.54  
 
2.22±0.42  
 
2.55±0.47  
 
3.35±0.84  
 
PT(seconds) 97.35±28.87  
 
21.98±5.86  
 
33.57±9.43  
 
13.1±2.486 
APTT(seconds) 124.57±54.94  
 
43.72±8.86  
 
59.94±23.15  
 
33.84±5.93  
 
MELD score 42(27-57) 23(15-46) 30(8-42)  
 
 
Table3.ALT-Alanine aminotransferase.AST-Aspartate amino transferase, Alk.Phosphtase-
Alkaline phosphatase, PT-Prothrombin time, APTT-Activated partial thromboplastin time. 
MELD score-Model end stage liver disease. 
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Risk factors for ATT induced liver failure  (compared to ATT induced acute hepatitis.)-
Clinical parameters 
                     Apart from assessing the clinical profile, the present study also looked into 
the risk factors that determine the development of liver failure (compared to acute hepatitis) 
following anti-TB DILI. Patients who have compensated or decompensated chronic liver 
disease already have poor hepatic reserve and synthetic function, and so they are at risk of 
anti TB DILI. Hence the acute on chronic liver failure group (ACLF) was excluded for this 
analysis. 
          The clinical parameters that determined the liver failure in anti TB-DILI were duration 
of ATT for more than 5 weeks(p=0.01),continuation of ATT despite symptoms(p=<0.001) 
and the presence of icterus(p=0.01).The laboratory parameters that were significantly 
different between the two groups include high serum bilirubin (p=<0.001),low 
albumin(p=<0.001),prolonged prothrombin time(p=0.002) and prolonged partial 
thromboplastin time(p<0.001).There was no significant difference between the two groups in 
terms of rise in liver enzyme or pattern of LFT(hepatocellular, choleststic or mixed).The two 
groups are compared in tables 4&5.On Multivariate analysis with logistic regression the 
factors that predicted liver failure  following anti-TB DILI were 1)continuation of drugs 
despite symptoms (p =0.003,odds ratio 7.74(95%CI -2.32-25.74) and 2)duration of ATT for 
more than 5 weeks(p=0.031,odds ratio 4.88(95% CI-1.351-15.79). 
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Risk factors for ATT induced liver failure  (compared to ATT 
induced hepatitis.)-Clinical parameters 
 
 
Variable Liver failure(n=28) 
 
Hepatitis(n=28) P value 
  ALF and SAHF 
Age(yrs) 38.32±15.14  
 
35.50±15.10  
 
0.52  
 
Females(n,%)  
 
12(42.8%) 13(46.4%)  
 
1 
Past h/o DILI(n,%) 2(7.1%)  
 
0 1 
Duration of ATT more than 5 Wks 
(n,%) 
16(57.1%) 6(21.4%) 0.01 
Continuation of ATT despite 
symptoms (n,%) 
19(67.8%) 6(21.4%) <0.001 
Alcohol(n) 2 1 1 
Diabetes (n) 5 4 1 
Underlying Chronic  hepatitis (n) 3 0 0.23 
Jaundice (n) 28 17 0.01 
Vomiting 17 18 1 
 
Table 4.  Liver failure includes ALF and SAHF (Acute on chronic liver disease is 
excluded). 
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Risk factors for ATT induced liver failure  (compared to ATT 
induced hepatitis.)-Laboratory   parameters at admission  
 
 
 
Variables Liver Failure  
(n=28) 
Hepatitis (n=28) P value 
ALF and SAHF 
Bilirubin 18.42±8.87 
 
3.85±3.51  
 
<0.001 
ALT 101(24-946) 129(45-564) 0.45 
AST 148(52-1116) 105(19-551) 0.1 
Alkaline phosphatase 188(59-688) 113(58-594) 0.1 
LFT pattern-
Hepatitic/cholestatic/mixed 
18/2/8 24/0/4 0.12 
Albumin 2.33±0.48 3.35±0.85 <0.001 
Prothrombin time 25.25(13.9-120) 13.5(9.5-18.6) 0.002 
Partial thromboplastin time 46.85(31-180) 32.3(23.8-48.9) <0.001 
 
Table 5.  Liver failure includes ALF and SAHF (Acute on chronic liver disease is 
excluded). 
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Prognostic factors in anti-TB DILI 
    
 
                     On univariate analysis, the clinical predictors of poor prognosis were- past 
history of anti -TB DILI (p=0.03),duration of ATT more than 5 weeks(p=0.004),continuation 
of ATT despite symptoms(p=0.04)and the presence of underlying CLD or chronic 
hepatitis(p=0.05).The presence of jaundice (p=0.001),hepatic encephalopathy(p<0.001) and 
ascites (p=0.03) at admission also predicted poor prognosis. The laboratory variables that 
determined poor outcome were high serum bilirubin (p<0.001), low albumin (p=0.003), 
prolonged prothrombin time(p=0.001) and partial thromboplastin time(p=0.001) as well as 
the presence of renal failure(p<0.001).The variables analysed in prognostic factors in anti -
TB DILI are  represented in tables 6,7. 
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Prognostic Factors in anti -TB DILI -Clinical parameters. 
 
 
    
Variables 
                                 
Survivors(n=42) 
         
Non survivors(n=21) 
                   
p value 
 
Age(yrs) 
 
38.93±16.82  
 
37.57±15.16  
 
0.76 
 
Females (n, %) 
 
17(40.4%) 
 
13(61.09%) 
 
0.10 
Past h/o DILI (n,%) 0 2 0.03 
Duration of ATT more than 5 Wks 
(n) 
14 15 0.004 
Continuation of ATT despite 
symptoms (n,%) 
17 14 0.04 
Alcohol(n) 2 2 0.4 
Diabetes (n) 8 4 1 
Underlying CLD/ Chronic  
hepatitis (n) 
4 6 0.05 
Jaundice (n) 30 21 0.001 
Vomiting 26 13 1 
Rash 5 3 0.7 
Hepatic encephalopathy 5 18 <0.001 
Ascites 16 14 0.03 
 
Table 6 
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Prognostic factors in anti- TB DILI-Laboratory variables. 
 
 
    
Variables 
                                       
Survivors(n=42) 
         
Non survivors(n=21) 
                    
  P value 
Bilirubin 4.6(0.4-26.8) 22.2(3.9-32.8) <0.001 
ALT 111.5(24-946) 141(54-920) 0.27 
AST 114.5(19-620) 257(73-1116) 0.08 
LFT pattern-
Hepatitic/cholestatic/mixed 
 
34/1/7 
 
13/2/6 
 
0.21 
Albumin 2.99±0.88 2.44±0.52 0.003 
Prothrombin time 14.45(9.5-49) 40(30-120) 0.001 
Partial thromboplastin time 36.5(23.8-59.5) 61.3(31-180) 0.001 
Complications 
 Renal failure 
 SBP 
 
1 
4 
 
8 
4 
 
<0.001 
0.29 
 
Table 7.ALT,-alanine amino transferase, AST-aspartate amino transferase,SBP-Spontaneous 
bacterial peritonitis 
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Predictors of outcome in anti-TB DILI with liver failure (ALF, SAHF&ACLF) 
  
                             In the present study a total of 35 patients presented with features of liver 
failure (ie., ALF, SAHF& ACLF).Of these 35 ,20 patients succumbed to the illness leading to 
an overall mortality of 57.1%.In the individual groups the mortality was 8(88.9%),8(42.1%) 
and 4(57.1%) for ALF,SAHF and ACLF respectively. The outcome in different groups is 
depicted in figure 3 .Subgroup analysis was done to identify the factors that predicted the 
outcome-survival or death. The factors found to be significant on univariate analysis were age 
(survivors 46.8±14.46 vs. non survivors 36.4±14.5, p =0.04), serum bilirubin (survivors 
13.48±8.1vs non survivors 22.9±8.36, p=0.002),prothrombin time(survivors 23.46±8.9 vs 
non survivors58.7±40.8,p=0.001),and MELD score(survivors 22±6 vs non survivors 
36±10,p<0.001). 
                              All continuous variables were dichotomised by the construction of receiver 
operating characteristics curves for identifying cut off values between the survivors and the 
non survivors. The curve was constructed using a value of serum bilirubin, prothrombin time 
and MELD score for each patient as independent variables and mortality as the outcome. The 
area under the curve was 0.787, 0.833 and 0.870 for serum bilirubin, prothrombin time and 
MELD score respectively. A cut off of s.bilirubin at 13 mg/dL was found to be 95% sensitive 
and 56% specific for predicting mortality. Prothrombin time greater than 23.3 sec was 85% 
sensitive and 76% specific for predicting mortality where as MELD score more than 23 was 
90% sensitive and 60% specific for predicting mortality. The odds ratio for s.bilirubin 
>13mg/dL was 21.71(95% CI,2.28-206.48),prothrombin time >23.3sec was 11.33(95% 
CI,2.21-57.87) and MELD score >23 was 21.71(95% CI ,2.28-206.48).The median (range) 
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time of death from the day of hospitalisation in ALF group was 5(1-8days),SAHF was 18(4-
41 days) and the ACLF was 5(4-18 days). 
 
 Outcome in anti-TB DILI with liver failure(ALF,SAHF& ACLF) and 
Hepatitis 
 
 
 
Figure3. .ALF-acute liver failure, SAHF-subacute hepatic failue,ACLF-acute on chronic liver 
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Determinants of outcome in anti-TB Liver failure(ALF,SAHF,ACLF) 
Variable Survivors(n=15) Non survivors(n=20) P value 
Age 46.8±14.46 36.4±14.5 0.04 
Bilirubin 13.48±8.1 22.9±8.36 0.002 
Prothrombin 23.46±8.9 58.7±40.8 0.001 
MELD score 22±6 36±10 <0.001 
Table 8MELD- Model end stage liver disease score 
 
Fig 4 Receiver operating charecteristic curve of serum bilirubin and mortality.Area under the 
curve is 0.787 
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Fig 5 Receiver operating charecteristic curve of  Prothrombin time and mortality. Area under 
the curve is 0.833 
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Fig 6 Receiver operating charecteristic curve of MELD score and mortality. Area under the 
curve is 0.870 
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                     Discussion 
                                   
 
                   The development of anti-TB DILI during chemotherapy is the most common 
reason for discontinuation of therapy and it results in inadequate as well as increased duration 
of therapy. A combination of INH, rifampicin and pyrazinamide produces more DILI than 
any of these drugs given alone. There is a wide variation in the incidence of anti- TB DILI in 
India in different studies as well as in the West (3%-30%) [43,44,81]. In an analysis of 
pooled data from four Indian studies ,the risk of clinical hepatitis due to anti tuberculosis 
drugs is estimated to be 11.5%.[20] ].In a prospective study from a tertiary care hospital in 
North India, Singh J etal reported ATT –ALF in 9.7% of their study population of 72 patients 
and the mortality was 85.7% [82]. In a recent study from AIIMS, ATT induced ALF 
constituted 70 of 1223 (5.7%) consecutive ALF patients admitted there over a period of 23 
yrs [15] with mortality of 67.1%.The present study has looked into the burden of ATT 
induced liver failure compared with ATT induced hepatitis and its  clinical significance. It is 
estimated that a patient taking ATT has a 0.01% risk of developing ALF [37]. However there 
are no prospective studies which have looked into the incidence of SAHF or ACLF following 
anti-TB DILI. Although the proportion of ALF patients may appear low, the absolute value 
will be very high because approximately 3 million people in India are suffering from 
tuberculosis and are on ATT. 
 
                                Several studies have looked into the risk factors for developing anti-TB 
DILI.It is still not clear why some patients develop DILI whereas some do not. It also not 
known who develop liver failure following anti-TB DILI , while the majority develop hepatic 
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adaptation. In the present study a total of 63 patients who developed different spectrum of 
anti- TB DILI were analysed. Here we used RUCAM score (the Roussel Uclaf Causality  
Assessment Model) for assessing the causality in anti-TB DILI.A score of >5(probable DILI) 
was taken as significant in defining DILI. 
 
                          In the liver failure group, 9 patients presented with ALF. Although many 
studies have not found any significant gender difference  in DILI, it has been observed that 
fulminent liver failure is more common in females and hence worse outcome including 
mortality[27].In the present study ALF was more common in females(5of 9,55.5%) and none 
survived.8 out of 9 patients with ALF died and overall mortality was 88.9%. There are  only 
2 published case reports of SAHF due to anti-TB DILI available in literature.[51,82].The 
current study has  the largest data  on SAHF due to anti-TB DILI(n=19).In SAHF group 
majority of patients were males(n=12,63.15%) and mortality was less compared to 
ALF(n=8,42.1%).They had a prolonged hospital stay before they discharged/died. 
Pyrazinamide is often associated with sub acute hepatic injury [41].All the patients in the 
SAHF group in the present study were on Pyrazinamide along with the other first line anti 
tuberculous drugs. Although it is known that underlying chronic liver disease is a risk factor 
for DILI, there is scarcity of published literature in ACLF due to anti-TB DILI. 7 patients in 
the present study  had ACLF ,the acute insult being  anti-TB DILI. Of these 6 patients were 
not known to have CLD prior to starting ATT. Majority were females (n=5,71.4%) and 
mortality in this group was 57.1%(n=4). 
                     
                        In the liver failure group majority of patients were on empiric ATT 
(n=17,48.5%), and the rest were on ATT for Pulmonary(n=10,28.5%) and extra pulmonary 
TB(n=8,22.5%).Most of the patients on empiric ATT were initiated by general practitioners 
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without proper evaluation, which could have been avoided. The most common clinical 
presentations in liver failure group was jaundice (97.1%), vomiting (60%), ascites (80%) and 
encephalopathy (65.7%).  
                         
                The reported incidence of anti TB DILI due to DOTS regimen is less. However 
Singla etal has reported the incidence to be around 14.3% in their study group which is as 
comparable with the daily regimen of ATT [20].But reports on liver failure due to DOTS is 
meagre. In the current study we came across 4 patients with liver failure who were on DOTS 
regimen. Hence it can be assumed that DOTS regimen may not decrease the incidence of 
mild or serious DILI due to anti TB drugs. In India, where acute HEV infection is endemic, 
viral hepatitis is always a confounder in ant-TB DILI. Sharma S.K has reported that 10-15% 
of suspected anti-TB DILI can have acute viral hepatitis [83] as a confounder. In the present 
study 3 patients had acute HEV infection and one had acute HBV infection. All were 
excluded as it was a part of exclusion criteria. Studies have shown that viral hepatitis will 
have larger rise in aminotrasferases and take longer time for normalisation of LFT as 
compared to anti-TB DILI and these patients can be safely restarted on regular ATT after 
normalisation of LFT.Hence routine screening of all patients with suspected anti-TB DILI for 
viral markers is recommended. 
 
                 Several studies have looked into the risk factors for anti-TB DILI. But why some 
patients develop liver failure, where as the others have a self limiting acute hepatitis is not 
clear. In the present study we had 35 patients of anti –TB DILI with liver failure which 
include ALF, SAHF and ACLF. Since it is known that chronic liver disease itself is a risk for 
developing acute liver failure, we excluded this group while analysing the risk factors for 
developing liver failure in comparison to acute hepatitis. On multivariate analysis the factors 
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that predicted liver failure were ,1) duration of ATT more than 5 weeks and 2)continuation of 
ATT despite having symptoms (p=0.031 and 0.003respectively).There was no difference 
between the two groups in terms of age, sex , underlying chronic hepatitis ,alcohol 
consumption. The liver failure group had significantly higher serum bilirubin, lower albumin, 
as well as prolongation of prothrombin time (p=<0.001 for all variables). 
                  Most of the studies have shown adverse outcome with the presence of 
encephalopathy, prolongation of prothrombin time. and high bilirubin [15].On comparing the 
survivor and non survivor groups,  on univariate analysis the presence of jaundice, 
encephalopathy  and ascites were significantly more in the non survival groups(p=0.001, 
<0.001 and 0.03 respectively).Also the non survivor group had significantly more patients 
who had ATT for more than 5 weeks and were continuing the drug despite symptoms.  High 
serum   bilirubin, prolongation of prothrombin time, low albumin and presence of renal 
failure were all higher in the non survivor group. The average serum bilirubin the non 
survivor group was 22.2mg/dL (range-3.9-32.8), which supports the Hy’s law. There was no 
significant difference between the two groups in terms of gender or pattern of LFT. 
             Despite optimal care (short of liver transplantation) majority of patients who came 
with liver failure due to anti-TB DILI died (20 of 35 patients-57.1%). Björnsson E et al, and 
O’ Grady JG reported older age to be a risk factor for poor outcome in DILI [33,34]. 
However we have observed a higher mortality in the younger age group In the liver failure 
group the patients who died were younger compared to those who survived (p=0.04).Also 
prothrombin time more than 23.3 seconds and MELD score above 23 were associated with 
mortality (Odds ratio- 11.33,95% CI,2.21-57.87and  21.71,95% CI ,2.28-206.48 
respectively). 
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                Conclusion 
              
                           In conclusion anti-TB DILI with liver failure is associated with high 
mortality(57.1%).Most common presentation in the liver failure group was 
SAHF(54.2%).ALF was more common in females and it was associated with very high 
mortality(88.9%). The presenting symptoms and complications were similar across the liver 
failure groups with longer hospital stay observed in the SAHF group. Majority of patients 
who developed anti-TB DILI were on empiric ATT (48.5%) which could have been avoided. 
Patients who continued   ATT despite having hepatitis symptoms and had duration of ATT 
for more than 5 weeks developed features of liver failure .Over all ,in the liver failure group 
serum bilirubin more than 13mg/dL, prothrombin time more than 23.3sec and MELD score 
above 23 were associated with poor outcome.  With the DOTS chemotherapy the risk of 
hepatotoxicity is less. So in future we may come across less number of anti-TB DILI. 
However in the present study, 4 patients developed liver failure while on DOTS regimen 
which is a cause for concern.  
                       The  future of anti-TB DILI research rests on studies that will help in  
identifying  genetic factors that are associated with susceptibility to serious anti-TB DILI  and 
biomarkers for identifying the development of potentially serious anti-TB DILI in the serum 
or urine of patients with anti-TB DILI.These might help in decreasing the incidence anti-TB 
liver failure. Based on the above conclusions the following recommendations can be made: 
1) ATT should not be prescribed without objective evidence of tuberculosis. 
2) Increased physician and patient awareness is needed in terms of the magnitude and 
seriousness of anti-TB DILI. 
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3) Monitoring for symptoms ,and LFT at regular intervals is important, at least for the initial 
2 months to pick up early anti-TB DILI and to prevent liver failure deaths. 
4) Patients with well compensated chronic liver disease may be initiated on regular ATT but 
with periodic monitoring of LFT during the treatment period. In those with decompensated 
chronic liver disease, although there is no clear recommendation, it may be wise to initiate 
them on non hepatotoxic regimen if clinically indicated. 
5) Patients with liver failure due to anti-TB DILI should be referred early to a tertiary centre 
with facilities for liver transplantation. Considering the scarcity of cadaveric donors in India, 
live related liver transplantation may merit advice. 
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                          Anti­TB DILI Proforma 
 
Name        
Age     
Sex    
Reason for ATT –  Empirical 
   PTB 
   Extra Pulmonary  
ATT Regimen  
Duration of ATT  
Continuation of ATT despite symptoms     Y/N 
 
Onset of symptoms  A symptomatic  
Symptoms – 
 RUQ abdominal Pain                                                      Y/N 
Jaundice,                                                     Y/N 
Anorexia Vomiting,                                             Y/N   
Fever                                                                                 Y/N 
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Skin rash                                                                           Y/N 
Arthralgia.                                                                          Y/N 
Interval between Jaundice to Encephalopathy 
 
Use of Alternative treatment 
Addictions – Ethanol/ Smoking  
 
Co morbidities – DM/HT// Underlying CLD/Ch Hepatitis 
Past h/o of DILI                                                               Y/N 
 
 
Clinical 
 Nutritional status-Ht            Wt                                          BMI  
General Examination 
Systemic Examination 
Grade of encephalopathy 
 
Laboratory  Values  
LFT – Baseline     Abnormal    Follow up 
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LFT Pattern Hepato cellular / Cholestatic/ or mixed  
 
PT/INR 
APTT 
Plasma Glucose  
 
BBVS 
 
IgM HAV / HEV 
 
ANA 
 
S.ceruloplasmin 
 
Immunoglobulin  
 
Absolute eosinophil count  
 
Imaging USG/CT abdomen  
 
Histology  
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Outcome :             Survived/Death/Liver Transplantation 
RUCAM score: 
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   Consent Form 
  
  I understand that Dr. ................is doing a study to assess the risk factors, prognostic 
factors and outcome in ATT induced Hepatitis. The study involves being interviewed (about 
the disease) and following up test reports done as part of your clinical care.  The results of the 
test done in connection with the study may not directly benefit me.  They are likely to 
indirectly benefit other patients with the disease. 
 
  I understand that my withdrawal from the study, at any time will not affect the 
treatment being given. 
 
 
Study Title: Clinical profile, prognostic factors and outcomes in anti Tuberculous drug 
induced liver injury’ 
Study Number: 
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age:_______ 
Please initial box  
(Subject) 
 
79 
 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [ ] 
(iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission  
to look at my health records both in respect of the current study and any further research that 
may be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
However, I understand that my identity will not be revealed in any information released to 
third parties or published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided such 
a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
 Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
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Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
 
 
 
 
 
 
 
 
 
 
 
